• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

    5/20/25 4:05:00 PM ET
    $CBLL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CBLL alert in real time by email

    SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time. 

    Event: William Blair 45th Annual Growth Stock Conference

    Date: Tuesday, June 3, 2025

    Time: 7:20 a.m. PST / 9:20 a.m. CST

    A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

    About CeriBell, Inc.

    Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ("AI")-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

    Investor Contact

    Brian Johnston or Laine Morgan

    Gilmartin Group

    [email protected] 

    Media Contact

    Corrie Rose

    [email protected]



    Primary Logo

    Get the next $CBLL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBLL

    DatePrice TargetRatingAnalyst
    4/4/2025$32.00Buy
    Ladenburg Thalmann
    11/5/2024$32.00Buy
    BofA Securities
    11/5/2024$30.00Buy
    Canaccord Genuity
    11/5/2024$32.00Overweight
    JP Morgan
    11/5/2024$31.00Buy
    TD Cowen
    11/5/2024Outperform
    William Blair
    More analyst ratings